Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Overcoming Resistance of Cancer Cells to PARP-1 Inhibitors with Three Different Drug Combinations

19 May 2016

Abstract excerpt

Inhibitors of poly[ADP-ribose] polymerase 1 (PARPis) show promise for treatment of cancers which lack capacity for homologous recombination repair (HRR). However, new therapeutic strategies are required in order to overcome innate and acquired resistance to these drugs and thus expand the array of cancers that could benefit from them. We show that human cancer cell lines which respond poorly to ABT-888 (a PARPi),...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CRISPR and Genetic Engineering
Share to DNA Repair Mechanisms
Share to PARP inhibition in cancer therapy

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 27196668
DOI: 10.1371/journal.pone.0155711

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Overcoming Resistance of Cancer Cells to PARP-1 Inhibitors with Three Different Drug CombinationsPMID 27196668Read ↗

Combination Treatment Strategies to Overcome PARP Inhibitor ResistanceSemantic proximity Read ↗

Co-targeting poly(ADP-ribose) polymerase (PARP) and histone deacetylase (HDAC) in triple-negative breast cancer: Higher synergism in BRCA mutated cells.Semantic proximity Read ↗

The PARP1 selective inhibitor saruparib (AZD5305) elicits potent and durable antitumor activity in patient-derived BRCA1/2-associated cancer modelsSemantic proximity Read ↗

PARP inhibitors in ovarian cancer: overcoming resistance with combination strategiesSemantic proximity Read ↗

Systems approach to rational combination therapy: PARP inhibitorsSemantic proximity Read ↗

PARP inhibitor and PRMT5 inhibitor synergy is independent of BRCA1/2 and MTAP status in breast cancer cellsSemantic proximity Read ↗

PARP1-SNAI2 transcription axis drives resistance to PARP inhibitor, TalazoparibSemantic proximity Read ↗

Thioparib inhibits homologous recombination repair, activates the type I IFN response, and overcomes olaparib resistanceSemantic proximity Read ↗

6-Thioguanine Selectively Kills BRCA2-Defective Tumors and Overcomes PARP Inhibitor ResistanceSemantic proximity Read ↗

PARP inhibitors synergize with gemcitabine by potentiating DNA damage in non‐small‐cell lung cancerSemantic proximity Read ↗

Modulation of Early Mitotic Inhibitor 1 (EMI1) depletion on the sensitivity of PARP inhibitors in BRCA1 mutated triple-negative breast cancer cellsSemantic proximity Read ↗

Response of Breast Cancer Cells to PARP Inhibitors Is Independent of BRCA StatusSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.